Evidence map›Paper›PMID 34079638›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2021

Diagnostic performance of

Ajalaya Teyateeti, Achiraya Teyateeti, Gregory C Ravizzini, Guofan Xu, Chad Tang, Shi-Ming Tu, Homer A Macapinlac, Yang Lu

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Cancers · 2022
    Article
  2. Positivity Rate of [Molecular imaging and biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ajalaya TeyateetiDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Achiraya TeyateetiDivision of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Thailand.
Gregory C RavizziniDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Guofan XuDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Chad TangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Shi-Ming TuDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Homer A MacapinlacDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Yang LuDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective study is to assess the performance of

Indexed as

18F-FluciclovinedetectionPET/CTProstate cancerPSArecurrence

Identifiers

PMID34079638
PMCPMC8165728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.